
|Videos|May 27, 2020
Targeting KRAS Mutations in Advanced NSCLC
Author(s)Targeted Oncology
Shared insight on recent advances in KRAS-mutant NSCLC, with a focus on new therapies on the horizon.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Ziftomenib in NPM1-Mutant Acute Myeloid Leukemia
2
FDA Approves Novel Interchangeable Biosimilar for Pertuzumab in HER2+ Breast Cancer
3
Five-Year CAR T Data Reflect Long-Term PFS in Multiple Myeloma
4
FDA Grants Fast Track to Alnodesertib Combo for Metastatic Colorectal Cancer
5






































